Class III Natural Health Product (NHP) applications in Canada require a more comprehensive regulatory assessment than Class I or Class II submissions. These applications generally involve products with medicinal ingredients, health claims, formulations or conditions of use that cannot be fully supported by Health Canada’s published monographs.
Under Health Canada’s updated Natural Health Products Management of Applications Policy (NHP MAP), Class III applications are subject to a 210-calendar-day service standard. Applicants must provide appropriate scientific evidence demonstrating the product’s safety, efficacy and quality under its proposed conditions of use.
Preparing a successful Class III application requires careful product classification, scientific evidence assessment, complete regulatory documentation and an understanding of Health Canada’s review process. Inadequate supporting evidence, inconsistencies between studies and proposed claims, or incomplete applications can result in Information Request Notices (IRNs), delays or application refusal.
A Class III Natural Health Product application is a Product Licence Application (PLA) submitted to Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) that requires a full assessment of the product’s safety, efficacy and/or quality.
Under the Natural Health Products Regulations, companies must obtain a product licence before selling an NHP in Canada. Once authorized, the product receives an eight-digit Natural Product Number (NPN) which must appear on its label.
Health Canada classifies NHP applications into three categories based on the extent to which the product can be supported by existing regulatory monographs and whether additional scientific assessment is required.
Class III applications typically involve products that fall outside the parameters of Health Canada’s published monographs. This may include novel ingredients, higher dosages, new health claims, modified formulations or ingredient combinations requiring additional evaluation.
For example, a manufacturer developing a botanical supplement with a health claim not supported by an existing Health Canada monograph may need to submit clinical studies or other scientific evidence demonstrating that the ingredient provides the proposed benefit at the recommended dosage.
Health Canada’s Natural Health Products Management of Applications Policy, updated in December 2025, provides the framework for determining application classification, preparing submissions and navigating the regulatory review process.
The primary distinction between the three application classes is the extent to which the product complies with Health Canada’s pre-assessed monographs and requires independent regulatory evaluation.
A monograph establishes accepted parameters for particular medicinal ingredients or products, including permitted dosages, recommended uses, routes of administration and risk information.
Products that comply with these parameters generally follow a more streamlined licensing pathway. Products requiring additional scientific assessment may fall under Class III.
| Requirement | Class I | Class II | Class III |
| Application type | Compendial | General or traditional | General, traditional, and homeopathic application types |
| Monograph support | Fully supported by one monograph | Generally supported by multiple monographs or other permitted Class II scenarios | Not fully supported by applicable monographs or requires additional assessment |
| Independent scientific evidence | Generally not required for safety and efficacy | Generally relies on accepted monograph-based evidence | Supporting evidence and/or a scientific rationale required for parameters not covered by applicable monographs. |
| Regulatory assessment | Monograph-based verification | Regulatory screening against applicable requirements | Regulatory screening followed by scientific assessment |
| Service standard | 60 calendar days | 90 calendar days | 210 calendar days |
| Typical example | Vitamin supplement fully compliant with one monograph | Multi-ingredient product supported by compatible monographs | Novel botanical extract with a new health claim |
These service standards are established in Appendix VI of the NHP MAP and include administrative screening and regulatory review.
A product containing several ingredients does not automatically require a Class III application. Similarly, the presence of a monographed ingredient does not guarantee eligibility for Class I or II. Classification depends on the complete formulation, proposed conditions of use and applicable Health Canada guidance.
Class III applications are required when a product falls outside the criteria for Class I and Class II and requires additional assessment of safety, efficacy and/or quality.
Health Canada’s updated NHP MAP identifies several circumstances that may require Class III review.
Products containing medicinal ingredients that are not adequately covered by Health Canada’s monographs may require independent scientific evidence.
For example, a company seeking an NPN for a novel botanical extract may need to provide information about the ingredient’s identity, manufacturing process, chemical composition, safety and proposed therapeutic effects.
Even where a related botanical species appears in an existing monograph, differences in the plant part, extraction method or chemical composition may affect whether that monograph can support the proposed product.
An NHP may contain ingredients already recognized by Health Canada but still require Class III review if the proposed health claim falls outside the applicable monograph.
For example, a botanical ingredient may be supported by a monograph for general digestive health. However, a manufacturer seeking to market the same ingredient for a different therapeutic purpose may need additional clinical evidence supporting that specific claim.
In these circumstances, existing monograph information may still support certain aspects of safety, while independent evidence is required to establish efficacy for the proposed claim.
Products using dosages, dosage forms or routes of administration that exceed or differ from monograph parameters may require Class III assessment.
Modified formulations intended to improve the absorption or bioavailability of medicinal ingredients, such as liposomal or phytosomal preparations, require Class III assessment unless specifically supported by the applicable monograph. Applicants cannot assume that evidence or monograph attestations for a conventional formulation establish the modified product’s safety and efficacy. The submission must justify the applicability of existing evidence and address any additional safety or efficacy considerations introduced by the delivery system. For example, a company developing a liposomal formulation of an established ingredient may need to demonstrate that the modified delivery system does not introduce additional safety concerns and that the supporting evidence remains applicable.
Some products may require Class III assessment even when their individual ingredients are supported by existing monographs.
Health Canada identifies certain combinations involving potentially additive pharmacological effects, interactions or increased safety concerns as requiring additional assessment.
Examples include combinations of stimulant laxatives and diuretics, or ingredients with overlapping hormonal effects.
Applicants must therefore evaluate the safety and efficacy of the complete formulation rather than assuming that individually acceptable ingredients will necessarily be acceptable in combination.
Class III applications must include sufficient evidence to demonstrate that the product is safe, effective and of acceptable quality under its recommended conditions of use.
The type and amount of evidence depend on the ingredient, proposed health claims, dosage, intended population and overall risk profile.
Health Canada’s Pathway for Licensing Natural Health Products Making Modern Health Claims establishes a risk-based framework for evaluating supporting scientific evidence.
Safety evidence must demonstrate that the product can be used under its proposed conditions without presenting unacceptable risks to consumers.
Depending on the product, supporting information may include toxicological studies, clinical safety data, published scientific literature, evidence of historical human exposure and information about potential interactions.
For example, a botanical ingredient proposed for daily consumption at a higher dosage than previously established may require additional evidence addressing repeated exposure and potential adverse effects.
Safety assessments should also consider the intended population, including whether the product is recommended for children, older adults or other potentially vulnerable groups.
Efficacy evidence must support the specific health benefits claimed in the application.
Depending on the claim and risk profile, Health Canada may consider randomized controlled trials, systematic reviews, observational studies and other relevant scientific literature.
For example, a manufacturer seeking authorization for a supplement intended to improve sleep quality may submit clinical studies evaluating the ingredient’s effects on relevant sleep outcomes.
However, the studies must be applicable to the proposed product. Evidence involving a different ingredient preparation, dosage or population may require additional justification before it can support the requested claim.
Class III applications must also address product quality, including the identity, composition, purity and specifications of medicinal ingredients and the finished product.
Health Canada’s NHP MAP submission guidance requires finished product specifications for Class II and III applications.
Depending on the product, relevant quality information may address ingredient characterization, potency, contaminants, microbiological quality and stability.
For example, a botanical extract standardized to a particular active constituent may require appropriate analytical specifications demonstrating the identity and quantity of that constituent.
Quality requirements should be evaluated alongside the scientific evidence, particularly when the studies supporting efficacy involve a specific extract, manufacturing process or chemical profile.
| Evidence Category | Examples | Regulatory Purpose |
| Clinical evidence | Randomized controlled trials, observational studies | Support proposed health claims and assess human safety |
| Scientific literature | Peer-reviewed publications, systematic reviews | Establish the scientific basis for safety or efficacy |
| Toxicological evidence | Repeated-dose studies, genotoxicity assessments | Evaluate potential safety risks |
| Traditional-use evidence | Recognized traditional medicine references | Support appropriate traditional-use claims |
| Ingredient characterization | Identity testing, chemical profiles, extract specifications | Establish ingredient identity and comparability |
| Finished product specifications | Potency, purity, microbial and contaminant limits | Demonstrate appropriate product quality |
| Scientific rationale | Evidence bridging, dose justification, formulation comparisons | Explain how existing evidence applies to the proposed product |
Not every Class III application requires a new clinical trial. Existing published evidence may be sufficient where it adequately supports the proposed product and its conditions of use.
However, applicants should evaluate the relevance, quality and limitations of available studies before determining whether additional research is necessary.
Health Canada’s current service standard for Class III Natural Health Product applications is 210 calendar days, including administrative screening, regulatory screening and scientific assessment.
This standard is established under the updated NHP MAP and applies to eligible applications proceeding through the standard review pathway.
The 210-day period should not be interpreted as a guaranteed approval timeline. Actual processing times may be affected by application completeness, Health Canada’s review workload, prioritization procedures and the need for additional information.
For example, a company submitting a Class III application with comprehensive safety and efficacy evidence may proceed through review without significant deficiencies. Another applicant submitting incomplete studies or inconsistent product information may receive an IRN requesting clarification, extending the overall time required to reach a regulatory decision.
Health Canada also identifies exceptions to the standard timeline, including certain Class III products requiring joint assessment with other directorates.
Under the updated NHP MAP, Health Canada requires new product licence applicants to confirm that their product is intended to be sold or manufactured in Canada within 12 months of receiving authorization.
This requirement is incorporated into the web-based PLA form and applies to Class I, II and III applications.
Health Canada has also clarified that applications are not necessarily reviewed strictly according to their original submission dates.
For applications submitted on or after December 15, 2025, review prioritization is based on the date Health Canada receives the application. Earlier submissions may follow different prioritization rules.
Companies planning a Canadian product launch should account for these procedures when establishing regulatory timelines and avoid treating the service standard as a fixed market-entry date.
Preparing a Class III application involves establishing the appropriate regulatory classification, evaluating the available scientific evidence and compiling the information required for Health Canada’s review.
The following process can help applicants identify potential deficiencies before submission.
Step 1: Confirm the Product’s Regulatory Classification
The first step is to determine whether the proposed product qualifies as an NHP and whether it meets the criteria for Class III review.
Applicants should review the medicinal ingredients, proposed health claims, dosages, routes of administration and applicable monographs.
Health Canada’s Natural Health Products Ingredients Database provides information on ingredients and links to relevant monographs.
Where a product does not fully comply with the applicable monograph parameters, the applicant should determine which aspects require additional evidence or scientific justification.
Step 2: Conduct a Scientific Evidence Gap Assessment
Before preparing the application, companies should evaluate whether the available evidence adequately supports the proposed product.
This involves reviewing the relevance of published studies, identifying missing safety or efficacy information and determining whether existing evidence can be applied to the proposed formulation.
For example, a company may have clinical evidence supporting a botanical ingredient at 500 mg daily but intend to market a product containing 1,000 mg daily.
The applicant would need to determine whether the available evidence adequately supports both safety and efficacy at the proposed dosage or whether additional information is necessary.
A gap assessment can help identify these issues before they become deficiencies during Health Canada’s review.
Step 3: Prepare the Product Licence Application and Supporting Documentation
Class III applications must include the information required under Section 5 of the Natural Health Products Regulations, together with applicable supporting documentation.
Depending on the product, this may include:
Health Canada strongly encourages applicants to include a summary report for Class III submissions, particularly when multiple studies, ingredients or scientific extrapolations are involved.
The report should explain how the supporting evidence relates to the product’s formulation, proposed claims, dosage and intended population.
Health Canada’s NHP MAP Appendix IV provides an example of a Class III summary report.
Step 4: Submit the Application to Health Canada
Applicants must submit the finalized PLA and supporting documents through the submission channel specified by Health Canada.
The updated NHP MAP requires electronic submission through the appropriate Connect account. Applications submitted through an incorrect channel or in an unacceptable format may be refused.
Before submission, companies should verify that the application classification is correct, all required documents are included and the information is consistent across the PLA, supporting studies and proposed labelling.
Step 5: Respond to Health Canada During Review
Once an application passes administrative and regulatory screening, Class III submissions proceed to scientific assessment.
During this stage, Health Canada evaluates whether the submitted evidence supports the product’s safety, efficacy and quality.
If additional information is required, the NNHPD may issue an Information Request Notice (IRN).
For example, Health Canada may request clarification concerning the relevance of a clinical study, the safety of an ingredient combination or the proposed dosage.
Applicants must respond within the specified deadline and provide information that addresses each identified deficiency.
For additional guidance, see dicentra’s article, How to Respond to a Health Canada Information Request Notice (IRN).
Class III applications may encounter delays or refusal when the submitted evidence does not adequately support the product’s proposed conditions of use or when regulatory requirements have not been met.
Health Canada’s updated NHP MAP identifies several potential grounds for refusal during regulatory screening and scientific assessment.
Common issues include insufficient safety evidence, unsupported health claims, incomplete application information and inadequate responses to IRNs.
For example, a manufacturer may submit a clinical study demonstrating that an ingredient supports a particular health benefit but fail to establish that the study’s ingredient preparation is comparable to the formulation being licensed.
Similarly, an application may include sufficient evidence supporting an ingredient’s safety but insufficient evidence demonstrating efficacy for the proposed claim.
| Deficiency | Potential Consequence | Recommended Approach |
| Unsupported health claims | Additional evidence requested or application refusal | Confirm that the evidence supports each proposed claim |
| Insufficient safety data | Safety concerns remain unresolved | Evaluate toxicological and clinical safety evidence |
| Dose discrepancies | Evidence may not support the proposed conditions of use | Ensure studies are relevant to the recommended dosage |
| Ingredient characterization gaps | Uncertainty regarding the identity or comparability of the ingredient | Provide appropriate specifications and characterization data |
| Incomplete quality documentation | Regulatory screening deficiencies or additional requests | Prepare complete finished product specifications |
| Inadequate evidence summary | Reviewers may have difficulty evaluating the submission | Provide a structured summary report linking evidence to claims |
| Incomplete IRN response | Application refusal | Address every deficiency within the specified deadline |
Applicants should evaluate these issues before submission, particularly where the proposed product involves novel ingredients, complex formulations or claims supported by limited clinical evidence.
Not necessarily. Health Canada does not require every Class III NHP application to be supported by a newly conducted clinical trial.
The evidence required depends on the proposed health claim, product characteristics, available scientific literature and overall risk profile.
For example, a manufacturer seeking authorization for a botanical extract may already have access to published clinical studies involving the same ingredient preparation and recommended dosage.
If those studies adequately support the proposed product’s safety and efficacy, additional clinical research may not be necessary.
However, products involving novel ingredients, new therapeutic claims or formulations that differ substantially from those evaluated in existing studies may require additional research.
Where evidence gaps cannot be addressed through published literature or an acceptable scientific rationale, a clinical trial may be an appropriate option.
Companies should determine whether new research is necessary through a regulatory and scientific evidence assessment before committing to the cost and timelines associated with clinical development.
Class III NHP applications often require specialized regulatory and scientific expertise to establish the appropriate licensing strategy, evaluate supporting evidence and prepare a complete submission.
With more than two decades of experience and over 24,000 regulatory and compliance projects, dicentra supports NHP manufacturers, ingredient suppliers and brand owners seeking authorization to market their products in Canada.
Our regulatory and scientific specialists assist with product classification, monograph assessments, safety and efficacy substantiation, scientific literature reviews, evidence gap assessments, Product Licence Applications and responses to Health Canada Information Request Notices.
Where existing scientific evidence is insufficient, dicentra’s clinical research capabilities can also support the development of additional evidence through appropriately designed clinical studies.
For companies manufacturing products outside Canada, dicentra offers NHP Importation Services through its established Canadian Site Licence. These services include foreign-site GMP assessments, product documentation review, Quality Assurance Person (QAP) oversight and finished-product release for eligible products.
While obtaining an NPN authorizes the product for sale, companies must also ensure that applicable manufacturing, importation and GMP requirements are satisfied before entering the Canadian market.
Whether you’re developing a novel Natural Health Product, seeking authorization for a new health claim or preparing a complex formulation for the Canadian market, understanding Health Canada’s evidence requirements is essential to developing an effective regulatory strategy.
Contact dicentra’s regulatory experts to discuss your Class III NHP application, evaluate your supporting scientific evidence and determine the appropriate product licensing pathway.